Lupin Limited · NSE:LUPIN
Lupin — Q4 FY2020 Earnings Presentation
25 slides from Lupin's earnings presentation, May 29, 2020
Slide 1: Exchange filing cover letter
May 29, 2020 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sirs, Sub: Q4 FY20 Investor Presentation. Pursuant to Regulation 30(2) read w
Slide 2: Investor Presentation Q4 FY2020
Investor Presentation Q4 FY2020 May 29, 2020
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Covid-19 Update
Covid-19 Update
Slide 5: Covid-19: Our Response
Covid-19: Our Response Employee Safety Business Continuity Commercial Strategy Employee Support • Travel restrictions enacted early • R&D and Manufacturing • Lockdown Phase • Employee engagement through to contain the spread facilities remained operational ✓ Digital engagement with interactive leade
Slide 6: “New Normal” Playbook - Safeguarding Health & Safety
“New Normal” Playbook - Safeguarding Health & Safety Clear SOPs on safety at all workplaces PG 5
Slide 7: “New Normal” Playbook - Safeguarding Health & Safety
“New Normal” Playbook - Safeguarding Health & Safety Field employees (India) mandated to attain Red Cross certification on Covid19 knowledge and prevention measures PG 6
Slide 8: Covid-19: Supporting Communities
Covid-19: Supporting Communities Launched a consolidated & very high Impact CSR program; Proactive coordination with Government agencies Supported Set up Lupin COVID-19 Crisis Response Fund Dedicated fund to support communities PG 7
Slide 9: Supporting Communities - #HeroesOfLupin
Supporting Communities - #HeroesOfLupin PG 8
Slide 10: Lupin – Awards and Accolades
Lupin – Awards and Accolades • McKesson Supplier of the Year Award - 2019 • Walmart Supplier of the Year Award - 2018 • Cardinal Supply Chain Excellence Award – 2018 • India Pharma Innovation of the Year 2019 - Department of Pharmaceuticals, Govt. of India • Operational Excellence in Manufacturing –
Slide 11: Business Review
Business Review
Slide 12: Lupin Today
Lupin Today Leading global pharmaceutical player Financial Metrics Globally Major Markets Market Cap (3) INR 401.6 bn 8th 3rd 3rd 6th 4th Revenue (FY20) INR 151.4 bn Largest Generic Largest Indian Largest in the India Pharma Largest South company Pharma US Market Rank2 Africa Generics EBITDA (FY20)
Slide 13: Q4 FY2020 Snapshot
Q4 FY2020 Snapshot Sales1 (INR mn, YoY Growth) Important developments Commercial India, North America, Mr. Nilesh.D.Gupta 11,921, 13% Managing Director • Robust growth in US led by seasonality and 15,791, (9%) Lupin Limited Levothyroxine ramp up Total • India Region Formulations outperformed (15% Yo
Slide 14: FY2020 Highlights
FY2020 Highlights FY2020 Sales Important developments (INR mn, YoY Growth) Commercial • Divested Japan Generics businesses (Kyowa and Kyowa CritiCare) India, North America, 51,385, 11% 58,212, 4% • bEnbrel launched in Japan Total • Levothyroxine approval and launch of 3 RLD’s 151,428, 6% • Robust gr
Slide 15: Key Exceptional Items – FY2020
Key Exceptional Items – FY2020 Kyowa Divestiture Gavis Impairment • Divested entire stake (99.82%) in our erstwhile Japanese • Changes in the pipeline value of Gavis portfolio, resulted in subsidiary, Kyowa Pharmaceutical to Unison Capital. The deal reassessment of the fair value of Gavis and except
Slide 16: Financial Results Review
Financial Results Review
Slide 17: P&L Highlights – Q4 FY2020
P&L Highlights – Q4 FY2020 % of QoQ % of % of YoY Amount in INR mn Q4 FY20 Q3 FY20 Q4 FY19 sales growth salessales growth Net sales 37,910 100.0% 37,161 100.0% 2.0% 38,070 100.0% (0.4%) Other operating income 547 532 796 Total revenue 38,457 37,693 2.0% 38,866 (1.1%) Gross profit 23,860 62.9% 23,568
Slide 18: P&L Highlights – FY2020
P&L Highlights – FY2020 Amount in INR mn FY20 % of sales FY19 % of sales YoY growth Net sales 151,428 100.0% 143,181 100.0% 5.8% Other operating income 2,320 3,465 Total revenue 153,748 146,646 4.8% Gross profit 97,122 64.1% 93,720 65.5% 3.6% (excl. other operating income) EBITDA 28,386 18.7% 28,937
Slide 19: North America
Q4FY20 North America 42% 35% YoY 4.1% QoQ 14.7% Strong QoQ growth on seasonality & Levo ramp up Consolidating our position in the US1 US quarterly sales ($ mn) 140 #3 #3 7 #4 120 6 245 30% average #4 129 123 100 #5 5 218 212 109 market share1 80 #6 4 184 186 60 79 83 3 40 57 65 63 2 44 45 51 20 28 1
Slide 20: India
Q4FY20 India 31% YoY 10.8% QoQ 8.1% India business continues to be robust Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) 4 Year CAGR% Lupin Rank1 13.1 13.4 13.0 MAT MAT 11.9 Therapy Market Lupin 10.5 Mar-16 Mar-20 Acute 9% 7% 13 13 Chronic 11% 15% 5 4 Cardiac 10%
Slide 21: Developed and Emerging Markets
Other Markets • Germany: EUR 9.3 mn sales in Q4 FY20 (up 31% YoY). EUR 36.2 mn sales in FY20 (up 26% YoY) EU5 • ARV’s, Inhalation and CNS are the key focus therapeutic segments Developed • NaMusclaTM - Broadening direct presence and partnering with country specific distribution partners • 4th large
Slide 22: R&D Investment – US$1 bn+ on R&D over the last 4 years
R&D Investment – US$1 bn+ on R&D over the last 4 years R&D spend (US$ mn) Strong FTF/Complex Gx launch pipeline (projection) 11.7% 13.5% 11.9% 10.5% 10.3% 5 7 16 19 9 Type 0 16.0% Inhalation 0 14.0% First to File 0 12.0% Biosimilar 0 10.0% Injectable 0 8.0% 0 337 6.0% 277 240 227 227 0 4.0% 0 2.0% 0
Slide 23: Regulatory Update
Regulatory Update
Slide 24: Quality and Compliance- Staying the Course
Quality and Compliance- Staying the Course 8 sites received consecutive positive outcomes from USFDA and other major agencies Agency Site Status Coral Spring, US EIR in Mar-20 Aurangabad EIR in Apr-20 Nagpur EIR in Apr-20 USFDA Mandideep Unit-2 EIR in Apr-20 Pithampur Unit-1 EIR in Apr-20 Vizag EIR
Slide 25: Thank You
THANK YOU SEE WWW.LUPIN.COM FOR DETAILS FOLLOW US ON